What is Flurbiprofen

CONTEXT:
The purpose of the study was to investigate the analgesic effect of a combination of flurbiprofen axetil intravenously and the relationship between opioid refractory pain relief levels and plasma β-endorphin in cancer patients and evaluate.
MATERIAL AND METHODS:
A total of 120 cancer patients were randomly divided into two groups, 60 patients took oral sulfate morphine sustained release tablets in Group A, and 60 other patients, combination treatment of axetil and opioids Intravenous flurbiprofen in group B. After 7 days, pain relief improves the quality of life and side effects were evaluated. In addition, β-endorphin plasma levels were measured by radioimmunoassay.
RESULTS:
With the combined treatment of axetil intravenous opioids and intravenous flurbiprofen, the total effective rate of pain relief has increased to 91.4% compared to 82.1% in the extended-release morphine sulfate tablet was used alone. Compared with group A, the analgesic effect in group B (p = 0.031) increased. He was also a satisfactory pain relief with a significant increase in plasma β-endorphin levels. After treatment, β-endorphin plasma levels in group B 62.4 ± 13.5 pg / ml, which is higher than in group A (45.8 ± 11.2 pg / ml) (p < 0.05).
CONCLUSION:
Our results suggest that the combination of intravenous flurbiprofen axetil and opioids may enhance the analgesic effect of opioids by increasing the levels of plasma beta-endorphin, which would give a selected and reliable strategy for the management of refractory cancer pain.